Researchers from University of Texas Medical Branch at Galveston developed a laser treatment that selectively destroys cancerous prostate tissue while preserving erectile and urinary functions. This technique is shown to be as effective as complete removal or radiation therapy with improved quality of life.
SourceUniversity of Texas Medical Branch at Galveston·JournalJournal of Vascular and Interventional Radiology·DateMar 20, 2019
Researchers at University of Alabama at Birmingham discovered androgen receptor imports into mitochondria, where it regulates multiple mitochondrial processes. This finding may lead to new treatment targets for castration-resistant prostate cancer.
SourceUniversity of Alabama at Birmingham·JournalJournal of Biological Chemistry·DateMar 19, 2019
Scientists have identified two coffee compounds, kahweol acetate and cafestol, which inhibit the growth of prostate cancer cells in cell culture and animal models. The study's findings suggest that these compounds may be used to treat drug-resistant prostate cancer, with further investigation needed.
SourceEuropean Association of Urology·JournalThe Prostate·DateMar 17, 2019
Apple iPhone 17 Pro
Apple iPhone 17 Pro delivers top performance and advanced cameras for field documentation, data collection, and secure research communications.
Researchers found that men with high neuroticism are more likely to experience adverse events after prostate cancer surgery, such as erectile dysfunction and incontinence. The study suggests that personality tests may be a valuable tool for identifying at-risk patients and improving care.
A new web tool, PREDICT Prostate, helps patients make informed decisions about treatment for early prostate cancer by providing a personalized prognosis and treatment options. The tool uses data from over 10,000 UK men to estimate survival rates and potential side effects of treatment.
SourceUniversity of Cambridge·JournalPLOS Medicine·DateMar 12, 2019
A new risk model developed by researchers can predict the survival of non-metastatic prostate cancer patients and the effect of different treatment approaches on survival. The PREDICT Prostate model uses data from over 10,000 men diagnosed with non-metastatic prostate cancer and has been validated in an external cohort.
The NRG Oncology trial suggests adding docetaxel-based chemotherapy to standard treatment should be considered for men with high-risk prostate cancer. The study found improved overall survival, disease-free survival, and reduced rates of distant metastases.
SourceNRG Oncology·JournalJournal of Clinical Oncology·DateMar 12, 2019
Scientists from Sanford Burnham Prebys Medical Discovery Institute identified how prostate cancer becomes treatment-resistant NEPC following targeted treatment. They found that an FDA-approved drug holds potential as a NEPC treatment and uncovered new therapeutic avenues to prevent transformation.
SourceSanford Burnham Prebys·JournalCancer Cell·DateFeb 28, 2019
SAMSUNG T9 Portable SSD 2TB
SAMSUNG T9 Portable SSD 2TB transfers large imagery and model outputs quickly between field laptops, lab workstations, and secure archives.
A phase III trial found hypofractionated radiotherapy (H-RT) to have similar QOL outcomes as conventional radiotherapy (C-RT) in men with low risk prostate cancer. H-RT delivers a total dose over a shorter period, reducing treatment duration and potential side effects.
Use of active surveillance for low-risk localized prostate cancer increased significantly between 2010 and 2015, becoming the dominant management strategy. Surgery rates declined among men with low-risk disease, while increasing in high-risk patients.
The use of active surveillance for low-risk prostate cancer nearly tripled between 2010 and 2015, with 42.1% of men adopting this strategy. This increase is associated with a favorable prognosis and reduced toxicity from treatment.
SourceDana-Farber Cancer Institute·JournalJAMA·DateFeb 11, 2019
A new UCLA-led study shows that men with low- or intermediate-risk prostate cancer can safely undergo higher doses of radiation over a significantly shorter period and still have the same successful outcomes as from a much longer course of treatment. The study analyzed data from 2,142 men treated with stereotactic body radiotherapy for...
SourceUniversity of California - Los Angeles Health Sciences·JournalJAMA Network Open·DateFeb 8, 2019
Meta Quest 3 512GB
Meta Quest 3 512GB enables immersive mission planning, terrain rehearsal, and interactive STEM demos with high-resolution mixed-reality experiences.
A new machine-learning framework distinguishes between low- and high-risk prostate cancer with higher precision than existing tools. The framework aims to provide radiologists and clinicians with a sound prediction tool for personalized patient care.
SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalScientific Reports·DateFeb 7, 2019
A new study suggests that enlarged prostates could impede tumor growth in prostate cancer patients. Computer simulations found that the mechanical stresses from an enlarging prostate keep tumors small. The findings challenge traditional treatments that involve downsizing the prostate.
SourcePurdue University·JournalProceedings of the National Academy of Sciences·DateFeb 4, 2019
Researchers at the University of Seville have characterized the normal electrical activity in PC-3 prostate cancer cells, showing a low-frequency pattern between 0.1 and 10 Hz. This study aims to explore the relationship between electrical patterns and cell proliferation, with potential applications for medicine delivery.
SourceUniversity of Seville·JournalSensors·DateFeb 4, 2019
A team of scientists at Queen Mary University of London is working on a novel approach to treat prostate cancer using a modified type of flu virus. The goal is to develop a new treatment that can target and kill cancer cells while leaving non-cancer cells unharmed. By modifying the virus to deliver it via the blood, the researchers hop...
Finasteride has been shown to reduce the risk of prostate cancer by 25 percent, with no significant increase in mortality rates. The study's findings have eliminated concerns over initial reports of potential risks, and doctors are now recommending finasteride as a preventive strategy for prostate cancer.
SourceSWOG·JournalNew England Journal of Medicine·DateJan 23, 2019
Apple Watch Series 11 (GPS, 46mm)
Apple Watch Series 11 (GPS, 46mm) tracks health metrics and safety alerts during long observing sessions, fieldwork, and remote expeditions.
Researchers at UIC will study mangosteen's phytochemicals and their impact on prostate cancer cells, with the goal of developing a new treatment approach. The $1.7M grant from NCI aims to investigate the unique xanthones in mangosteen that promote androgen receptor degradation.
Researchers have discovered that the GREB1 gene amplifies androgen receptor output in human prostate cancer cells, contributing to antiandrogen resistance. Inhibiting GREB1 converts high-AR output cells to low-output states, improving enzalutamide treatment effectiveness.
Researchers identified a link between BRCA2 mutations and aggressive prostate cancer in men, increasing their risk of developing other cancers. The study also found that patients with BRCA2 mutations have poorer treatment responses and outcomes.
SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalJournal of Clinical Oncology·DateJan 9, 2019
Researchers identified genetic alterations in low-risk prostate cancers that may indicate higher-risk cancer presence, guiding men to consider treatment. The study suggests a potential test to validate these alterations, enabling personalized treatment decisions.
SourceMayo Clinic·JournalMayo Clinic Proceedings·DateJan 3, 2019
Recent advancements in prostate imaging modalities have significantly enhanced the diagnosis of prostate cancer. Androgen receptor-based imaging is emerging as a promising approach for non-invasive detection using non-steroidal antiandrogen agents.
SourceBentham Science Publishers·JournalCurrent Pharmaceutical Design·DateDec 24, 2018
AmScope B120C-5M Compound Microscope
AmScope B120C-5M Compound Microscope supports teaching labs and QA checks with LED illumination, mechanical stage, and included 5MP camera.
A recent study published in the Journal of Clinical Oncology found that time to biochemical failure can be used as a surrogate endpoint for locally advanced prostate cancer treatment, reducing overall survival benefit by 6% compared to traditional endpoints. The analysis of NRG-RTOG 9202 clinical trial results showed significant associ...
SourceNRG Oncology·JournalJournal of Clinical Oncology·DateDec 20, 2018
A recent study suggests that black men diagnosed with low-risk prostate cancer (Gleason score 6) may have a more aggressive form of the disease, leading to higher mortality rates compared to non-black men. The research found a significant disparity in prostate cancer death rates between black and non-black patients with Gleason 6 cancers.
SourceDana-Farber Cancer Institute·JournalJAMA·DateDec 18, 2018
A new assay can analyze small amounts of material to estimate metastatic risk, enhancing prostate cancer evaluation. The Next-Generation Copy Number Alteration (NG-CNA) assay is a targeted amplification sequencing technique that can process samples faster and decrease the cost per sample.
SourceElsevier·JournalJournal of Molecular Diagnostics·DateDec 12, 2018
A 29-year study found that only 12% of men with advanced prostate cancer were saved from dying by surgery, while 80% had died after 29 years. Surgery did extend life expectancy by 2.9 years, but also came with significant side effects.
SourceUppsala University·JournalNew England Journal of Medicine·DateDec 12, 2018
A team of researchers has created a computer model using cancer patient data to predict the course of disease for prostate cancer. The model, currently being implemented at a clinic in Germany, can identify key mutations that trigger the disease.
SourceUniversity of Copenhagen - The Faculty of Health and Medical Sciences·JournalCancer Cell·DateDec 11, 2018
DJI Air 3 (RC-N2)
DJI Air 3 (RC-N2) captures 4K mapping passes and environmental surveys with dual cameras, long flight time, and omnidirectional obstacle sensing.
PSMA-targeted PET/MRI performs equally well as clinical nomograms to determine risk for advanced disease in high-risk prostate cancer patients, providing valuable information for treatment planning. The study results show whole-body imaging with 68Ga-PSMA-11 PET/MRI offers a one-stop shop for staging and guiding treatment options.
SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateDec 11, 2018
A 20-year study from Northwestern Medicine found men with inflammatory bowel disease have four to five times higher risk of prostate cancer and elevated PSA values. Researchers are now investigating the mechanism behind gut inflammation leading to prostate cancer.
SourceNorthwestern University·JournalEuropean Urology·DateDec 7, 2018
A new medical software system, SmartTarget, enhances prostate cancer detection by overlaying MRI scans onto ultrasound images, guiding surgeons during biopsies. The technology has shown that combining both techniques can detect clinically relevant cancers missed with current methods.
SourceUniversity College London·JournalEuropean Urology·DateDec 5, 2018
A study of 150 popular YouTube videos on prostate cancer found that 77% had factual errors or biased content, while only 53% adequately described potential harms and side effects. Researchers urge viewers to consult credible sources for accurate information on prostate cancer.
SourceNYU Langone Health / NYU Grossman School of Medicine·JournalEuropean Urology·DateNov 27, 2018
A new study has identified a novel molecular driver of lethal prostate cancer and a molecule that could be used to attack it. The findings, if confirmed in humans, could lead to more effective ways to control certain aggressive types of prostate cancer.
SourceCedars-Sinai Medical Center·JournalNature Medicine·DateNov 26, 2018
Aranet4 Home CO2 Monitor
Aranet4 Home CO2 Monitor tracks ventilation quality in labs, classrooms, and conference rooms with long battery life and clear e-ink readouts.
Researchers found that combining surgery with post-operative low-dose radiation and hormone therapy reduces prostate cancer death risk to less than 10% for men with aggressive prostate cancer. In contrast, surgery alone increases the risk of death from prostate cancer within five years.
SourceBrigham and Women's Hospital·JournalJAMA Oncology·DateNov 15, 2018
A study led by CNIO has defined a blood-based biomarker that can determine the most effective treatment for castration-resistant prostate cancer patients. The biomarker, which analyzes the presence of a specific gene in circulating tumour DNA, shows promise for improved survival rates and personalized therapy.
SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·JournalEuropean Urology·DateNov 13, 2018
Researchers used PSMA PET/CT to detect prostate cancer outside the prostate gland with higher sensitivity and specificity than standard imaging techniques. This improved accuracy enables more precisely targeted treatment, potentially increasing the chances of successful outcomes.
SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateNov 8, 2018
A study of 1244 patients found a 72% higher risk of heart failure in those receiving androgen deprivation therapy compared to non-users. The researchers recommend counseling patients on modifiable heart failure risk factors and providing cardiovascular examinations.
SourceWiley·JournalThe Journal of Clinical Pharmacology·DateNov 7, 2018
Fluke 87V Industrial Digital Multimeter
Fluke 87V Industrial Digital Multimeter is a trusted meter for precise measurements during instrument integration, repairs, and field diagnostics.
Researchers will identify biomarkers for DNA repair defects in tumors, enabling faster decision-making on treatment choices. A clinical trial will test carboplatin therapy's effectiveness in advanced prostate cancer.
SourceCentro Nacional de Investigaciones Oncológicas (CNIO)·DateNov 6, 2018
A study found that men with prostate cancer value quality of life and will trade off survival odds for fewer side effects, including urinary incontinence and impotence. The research suggests that patients may prefer less invasive treatments like focal therapy or active surveillance to reduce harm.
SourceNational Cancer Research Institute·DateNov 4, 2018
Researchers at the University of Notre Dame have found a way to inhibit T-cell activation by targeting nitration of an amino acid in cancer cells. This approach could enhance cancer immunotherapy by identifying activity-based markers and designing approaches that shut down specific mechanisms inhibiting T-cell activation.
SourceUniversity of Notre Dame·JournalProceedings of the National Academy of Sciences·DateOct 29, 2018
Garmin GPSMAP 67i with inReach
Garmin GPSMAP 67i with inReach provides rugged GNSS navigation, satellite messaging, and SOS for backcountry geology and climate field teams.
A new type of molecule blocks the action of genes that drive therapy-resistant prostate cancer growth, reducing cell proliferation by 95%. The cyclic peptoids also blocked a key growth signal in live animal tests.
SourceNYU Langone Health / NYU Grossman School of Medicine·JournalNature Communications·DateOct 23, 2018
A large, long-term study found SBRT to be safe and effective for men with low- and intermediate-risk prostate cancer. The treatment delivered substantially larger doses of radiation per session, reducing the duration of treatment without increasing the risk of severe side effects.
SourceAmerican Society for Radiation Oncology·DateOct 22, 2018
The SPPORT trial found that adding pelvic lymph node treatment and short-term hormone therapy to standard treatment extends time before cancer spreads. This combination therapy resulted in higher freedom-from-progression rates and lower distant metastasis rates compared to standard treatments alone.
SourceAmerican Society for Radiation Oncology·DateOct 22, 2018
A new analysis of genetic data and clinical trial results suggests that African-American men may have comparatively higher cure rates when treated with radiation therapy. The study found that tumors from African-American men were more likely to have indicators of increased sensitivity to radiation, leading to improved outcomes.
SourceAmerican Society for Radiation Oncology·DateOct 22, 2018
GQ GMC-500Plus Geiger Counter
GQ GMC-500Plus Geiger Counter logs beta, gamma, and X-ray levels for environmental monitoring, training labs, and safety demonstrations.
A large comparison study found that radiotherapy to the prostate improved failure-free survival but not overall survival in men with newly diagnosed metastatic prostate cancer and a low burden of disease. The treatment was well-tolerated, with only modest side effects.
SourceEuropean Society for Medical Oncology·JournalAnnals of Oncology·DateOct 21, 2018
Researchers at City of Hope have developed a synthetic DNA molecule that disables tumor defense systems while inducing immune responses, eliminating difficult-to-treat prostate cancer in experimental models. The novel two-step strategy relies on two opposite actions of the same 'hot and cold' molecule to remove obstacles to treating me...
SourceCity of Hope·JournalClinical Cancer Research·DateOct 18, 2018
A new test developed by scientists at the University of York can accurately identify life-threatening prostate cancers, which could lead to fewer unnecessary surgeries and radiotherapies. The test has shown a high accuracy rate of up to 92%, potentially reducing healthcare costs and side effects for patients.
SourceUniversity of York·JournalBritish Journal of Cancer·DateOct 18, 2018
Recent studies conducted by CHAAMPS reveal significant health disparities among black men, including racial disparities in hospitalizations for heart failure. Additionally, the organization aims to address violent encounters between police and young black men through community-based initiatives.
SourceElsevier·JournalAmerican Journal of Preventive Medicine·DateOct 17, 2018
The new guideline recommends moderate hypofractionation (240-340 cGy) as an alternative to conventional fractionation for men with early-stage prostate cancer. Hypofractionated radiation therapy can be completed in four to five weeks, compared to eight to nine weeks for conventional radiation.
SourceAmerican Society for Radiation Oncology·JournalPractical Radiation Oncology·DateOct 11, 2018
Celestron NexStar 8SE Computerized Telescope
Celestron NexStar 8SE Computerized Telescope combines portable Schmidt-Cassegrain optics with GoTo pointing for outreach nights and field campaigns.
A new study finds that baseline PSA levels measured at midlife strongly predict total and aggressive prostate cancer in black men years later. The research suggests targeted screening based on a midlife PSA might identify black men at high risk while minimizing screening in those at low risk.
SourceBrigham and Women's Hospital·JournalEuropean Urology·DateOct 10, 2018
Researchers at UCLA have discovered that late-stage prostate and lung cancers share common molecular mechanisms. The study found that these cancers can evolve similarly, even from different organs, which could lead to the development of drugs to treat not just prostate and lung cancers but also small cell cancers of almost any organ.
SourceUniversity of California - Los Angeles Health Sciences·JournalScience·DateOct 4, 2018
Researchers are developing a robot that can detect and treat prostate cancer more accurately, reducing the need for invasive procedures. The robot will guide a steerable flexible needle to target cancer cells, while AI and mathematical modeling ensure precise placement of radioactive material.
Apple MacBook Pro 14-inch (M4 Pro)
Apple MacBook Pro 14-inch (M4 Pro) powers local ML workloads, large datasets, and multi-display analysis for field and lab teams.
Researchers have discovered a potential treatment for prostate cancer using riluzole, a drug approved for ALS treatment. The study found that riluzole promotes the degradation of androgen receptors, which drives prostate cancer growth.
A new study finds that baseline PSA levels in black men between 40 and 60 can strongly predict future development of prostate cancer and its most aggressive forms. Elevated PSA levels are associated with increased risk, even among those within the normal range.
SourceH. Lee Moffitt Cancer Center & Research Institute·JournalEuropean Urology·DateOct 2, 2018
A new pathology test using AI can accurately predict clinically significant prostate cancer disease progression following surgery, helping guide treatment decisions. The Precise MD post-op test reclassified 58% of intermediate risk patients as low risk and 42% as high risk for significant disease progression.
SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalProstate Cancer and Prostatic Diseases·DateOct 2, 2018
A recent study published in the journal Cancer found that patients with locally advanced prostate cancer who received a combination of prostate removal and radiation therapy had a higher rate of survival compared to those treated with radiation alone. The study analyzed data from over 13,000 men diagnosed with high-risk prostate cancer...
SourceThomas Jefferson University·JournalCancer·DateSep 25, 2018
CalDigit TS4 Thunderbolt 4 Dock
CalDigit TS4 Thunderbolt 4 Dock simplifies serious desks with 18 ports for high-speed storage, monitors, and instruments across Mac and PC setups.
A Phase III clinical trial is enrolling men with metastatic Stage 4 prostate cancer to compare standard systemic therapy with or without surgery or radiation therapy. The goal is to delay disease progression and improve survival.
SourceLouisiana State University Health Sciences Center·DateSep 25, 2018
A survey of over 2,500 respondents found low awareness of urological conditions, particularly among men. Men are less knowledgeable about urological symptoms than women, and many do not take early signs seriously, leading to delayed diagnosis and potentially life-threatening consequences.
Researchers developed an mRNA-based nanotherapeutic to reintroduce functional copies of PTEN into cancer cells, restoring tumor suppressor function and killing cancer cells. The therapy showed significant suppression of tumor growth and progression in mouse models of prostate cancer.
SourceBrigham and Women's Hospital·JournalNature Biomedical Engineering·DateSep 17, 2018
A study estimates that prostate cancer screening and treatment for older men costs Medicare over $1.2 billion annually. The majority of this cost goes towards treating low-grade disease with Gleason scores of 6, which may not significantly impact life expectancy.
SourceUNC Lineberger Comprehensive Cancer Center·JournalJAMA Oncology·DateSep 13, 2018
A research team at the University of Turku discovered a link between HOXB13 and CIP2A genes and aggressiveness of prostate cancer. The simultaneous expression of these two gene variants predisposes men to get prostate cancer earlier in life and stimulates tumor formation.
SourceUniversity of Turku·JournalClinical Cancer Research·DateSep 11, 2018
Apple iPad Pro 11-inch (M4)
Apple iPad Pro 11-inch (M4) runs demanding GIS, imaging, and annotation workflows on the go for surveys, briefings, and lab notebooks.